KeyCorp Has Lowered Expectations for Progyny (NASDAQ:PGNY) Stock Price

Progyny (NASDAQ:PGNY) had its price target reduced by research analysts at KeyCorp from $32.00 to $28.00 in a report released on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. KeyCorp’s price objective indicates a potential upside of 59.82% from the company’s previous close.

A number of other brokerages have also recently issued reports on PGNY. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a report on Monday, December 29th. Citigroup raised Progyny to an “outperform” rating in a research note on Tuesday, January 20th. BTIG Research reaffirmed a “buy” rating on shares of Progyny in a research note on Wednesday, January 21st. JPMorgan Chase & Co. set a $35.00 price target on shares of Progyny in a research report on Wednesday, January 21st. Finally, Canaccord Genuity Group boosted their price objective on shares of Progyny from $23.00 to $26.00 and gave the company a “hold” rating in a research report on Monday, November 17th. Eight analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $28.80.

Progyny Trading Down 0.5%

Shares of NASDAQ PGNY opened at $17.52 on Monday. The stock’s 50-day moving average is $23.56 and its 200 day moving average is $23.04. The stock has a market cap of $1.43 billion, a price-to-earnings ratio of 26.95, a P/E/G ratio of 1.20 and a beta of 1.01. Progyny has a 1-year low of $16.75 and a 1-year high of $28.75.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The business’s quarterly revenue was up 6.7% on a year-over-year basis. During the same period last year, the business earned $0.42 earnings per share. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, analysts forecast that Progyny will post 0.6 EPS for the current fiscal year.

Hedge Funds Weigh In On Progyny

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada boosted its position in Progyny by 384.8% during the 1st quarter. Royal Bank of Canada now owns 13,027 shares of the company’s stock valued at $291,000 after acquiring an additional 10,340 shares in the last quarter. Amundi grew its stake in Progyny by 103.8% in the first quarter. Amundi now owns 11,419 shares of the company’s stock worth $264,000 after purchasing an additional 5,817 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Progyny by 6.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,032 shares of the company’s stock worth $5,630,000 after purchasing an additional 14,297 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Progyny by 249.3% during the second quarter. Nisa Investment Advisors LLC now owns 11,613 shares of the company’s stock valued at $255,000 after buying an additional 8,288 shares during the period. Finally, Y Intercept Hong Kong Ltd boosted its holdings in shares of Progyny by 88.0% during the 2nd quarter. Y Intercept Hong Kong Ltd now owns 56,196 shares of the company’s stock valued at $1,236,000 after buying an additional 26,310 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.